European Journal of Pediatrics

, Volume 153, Issue 8, pp 569–573 | Cite as

Cystic fibrosis screening in neonates — measurement of immunoreactive trypsin and direct genotype analysis for ΔF508 mutation

  • J. Larsen
  • S. Campbell
  • E. B. Faragher
  • M. Götz
  • I. Eichler
  • S. Waldherr
  • K. Dobianer
  • J. Spona
Original Paper

Abstract

This study investigated the clinical usefulness of screening for cystic fibrosis (CF) in 19992 newborns, over 39 months, in an Austrian population. Immunoreactive serum trypsin (IRT) determination was followed by sweat chloride analysis (sweat test) to establish diagnosis. In a retrospective analysis covering 6 months of the study period, individuals who were considered to be at risk after IRT estimation (n = 22) were analysed for ΔF508 mutation, using a new method of DNA extraction from the initial dried blood specimens. A total of 119 infants (0.6%) had values greater than 750mg trypsin/ml whole blood. In 88 babies sweat tests were performed, leading to the diagnosis of CF in 11 cases. One patient was not initially identified by screening but was later discovered due to his clinical status. Three infants were noted to carry the ΔF508 mutation (1 homozygous, 2 heterozygous). Two of these babies already had CF. The second heterozygote was a carrier. A highly efficient three tier screening strategy is presented in which IRT estimation, determination of ΔF508 status and sweat chloride testing could lead to a high sensitivity analysis of this population.

Key words

Cystic fibrosis Screening Infant Trypsin Mutation 

Abbreviations

CF

cystic fibrosis

IRT

immunoreactive trypsin

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Al-Jader LN, Goodchild MC, Ryley HC, Harper PS (1990) Attitudes of parents of cystic fibrosis children towards neonatal screening and antenatal diagnosis. Clin Genet 38: 460–465Google Scholar
  2. 2.
    Ballabio A, Gibbs RA, Caskey CT (1990) PCR test for cystic fibrosis deletion. Nature 343: 220Google Scholar
  3. 3.
    Bowling F, Cleghorn G, Chester A, Curran J, Griffin B, Prado J, Francis P, Shepherd R (1988) Neonatal screening for cysticfibrosis. Arch Dis Child 63: 196–198Google Scholar
  4. 4.
    Bowling FG, McGill JJ, Shepherd RW, Danks DM (1990) Screening for cystic fibrosis: use of ΔF508 mutation. Lancet 335: 925–926Google Scholar
  5. 5.
    Chatfield S, Qwen G, Ryley HC, Williams J, Alfaham M, Goodchild MC, Weller P (1991) Neonatal screening for cystic fibrosis in Wales and the West Midlands: clinical assessment after five years of screening. Arch Dis Child 66: 29–33Google Scholar
  6. 6.
    Crossley JR, Elliott RB, Smith PA (1979) Dried-blood spot screening for cystic fibrosis in the newborn. Lancet 1: 472–474Google Scholar
  7. 7.
    Cutting GR, Kasch LM, Rosenstein BJ, Zielenski J, Tsui L-C, Antonarakis SE, Kazazian HH Jr (1990) A cluster of cystic fibrosis mutations in the first nucleotide-binding fold of the cystic fibrosis conductance regulator protein. Nature 346: 366–369Google Scholar
  8. 8.
    Dankert-Roelse JE, Meerman GJ te, Martijn A, Kate LP ten, Knol K (1989) Survival and clinical outcome in patients with cystic fibrosis, with or without neonatal screening. J Pediatr 114: 362–367Google Scholar
  9. 9.
    Duhammel JF, Travert G, Delmas P, Bronard J, Venezia R (1984) Special features of the time related evolution in IRT blood levels in six out of seven newborns with cystic fibrosis complicated by meconium ileus. In: Lawson D (ed) Cystic fibrosis: horizons. John Wiley and Sons, Chichester, p 208Google Scholar
  10. 10.
    Gibson LE (1973) The decline of the sweat test. Clin Pediatr 12: 450–453Google Scholar
  11. 11.
    Gibson LE, Cooke RE (1959) A test for concentration of electrolytes in sweat in cystic fibrosis of the pancreas utilizing pilocarpine by iontophoresis. Pediatrics 23: 545–549Google Scholar
  12. 12.
    Hammond KB, Abman SH, Sokol RJ, Accurso FJ (1991) Efficacy of statewide neonatal screening for cystic fibrosis by assay of trypsinogen concentrations. N Engl J Med 325: 769–774Google Scholar
  13. 13.
    Jinks DC, Minter M, Tarver DA, Vanderford M, Hejtmancik JF, McCabe ERB (1989) Molecular genetic diagnosis of sickle cell disease using dried blood specimens on blotters used for newborn screening. Hum Genet 81: 363–366Google Scholar
  14. 14.
    Kerem B-S, Rommens JM, Buchanan JA, Markiewicz D, Cox TK, Chakravarti A, Buchwald M, Tsui L-C (1989) Identification of the cystic fibrosis gene: genetic analysis. Science 245: 1073–1080Google Scholar
  15. 15.
    Larsen J, Georghiou A, Kury FD, Götz M, Sanz K, Dobianer K, Spona J (1992) Frequency of ΔF508 mutation and haplotype analysis in Austrian cystic fibrosis families. Hum Genet 89: 464–465Google Scholar
  16. 16.
    Marcus MS, Sondel SA, Farrell PM, Laxova A, Carey PM, Langhough R, Mischler EH (1991) Nutritional status of infants with cystic fibrosis associated with early diagnosis and intervention. Am J Clin Nutr 54: 578–585Google Scholar
  17. 17.
    Peres O, Briard ML, Lemonnier F, Pasquet-Ferre C, Blandin C, Travert G, Fernandez Y (1990) Neonatal cystic fibrosis screening: new trends. Arch Fr Pediatr 47: 251–253Google Scholar
  18. 18.
    Ranieri E, Ryall RG, Morris CP, Nelson PV, Carey WF, Pollard AC, Robertson EF (1991) Neonatal screening strategy for cystic fibrosis using immunoreactive trypsinogen and direct gene analysis. BMJ 302: 1237–1240Google Scholar
  19. 19.
    Rock MJ, Mischler EH, Farrell PM, Wei L-J, Bruns WT, Hassemer DJ, Laessig RH (1990) Newborn screening for cystic fibrosis is complicated by age-related decline in inimunoreactive trypsinogen levels. Pediatrics 85: 1001–1007Google Scholar
  20. 20.
    Ryley HC, Goodchild MC, Dodge JA (1992) Screening for cystic fibrosis. Br Med Bull 48: 805–822Google Scholar
  21. 21.
    Schneeberger C, Kury F, Larsen J, Speiser P, Zeillinger R (1992) A simple method for extraction of DNA from Guthrie cards. PCR Methods Applic 2: 177–179Google Scholar
  22. 22.
    Spence WC, Paulus-Thomas J, Orenstein DM, Naylor EW (1993) Neonatal screening for cystic fibrosis: addition of molecular diagnostics to increase specificity. Biochem Med Metab Biol 49: 200–211Google Scholar
  23. 23.
    Tsui LC (1992) The spectrum of cystic fibrosis mutations. Trends Genet 8: 392–398Google Scholar
  24. 24.
    Weller PH, West JV (1991) Neonatal screening — should we or shouldn't we? J Roy Soc Med 84 [Suppl 18]: 7–9Google Scholar
  25. 25.
    Wilcken B, Brown ARD, Urwin R, Brown DA (1983) Cystic fibrosis screening by dried blood spot trypsin assay: results in 75,000 newborn infants. J Pediatr 102: 383–387Google Scholar
  26. 26.
    Wilcken B, Chalmers G (1985) Reduced morbidity in patients with cystic fibrosis detected by neonatal screening. Lancet II: 1319–1321Google Scholar
  27. 27.
    Wilfond BS, Fost N (1990) The cystic fibrosis gene: medical and social implications for heterozygote detection. J Am Med Assoc 263: 2777–2783Google Scholar

Copyright information

© Springer-Verlag 1994

Authors and Affiliations

  • J. Larsen
    • 1
    • 2
  • S. Campbell
    • 3
  • E. B. Faragher
    • 4
  • M. Götz
    • 5
  • I. Eichler
    • 5
  • S. Waldherr
    • 1
  • K. Dobianer
    • 1
  • J. Spona
    • 1
    • 6
  1. 1.Department of Cellular EndocrinologyLudwig Boltzmann Institute for Experimental EndocrinologyViennaAustria
  2. 2.Department of SurgeryUniversity Hospital of South ManchesterManchesterUK
  3. 3.Department of Obstetrics and GynaecologyUniversity Hospital of South ManchesterManchesterUK
  4. 4.Medical StatisticsUniversity Hospital of South ManchesterManchesterUK
  5. 5.Department of PaediatricsUniversity of ViennaAustria
  6. 6.First Department of GynaecologyUniversity of ViennaAustria

Personalised recommendations